Enjoy water sports & leisure with enhanced safety ✔ Discover lightweight, compact RESTUBE safety buoys! → Experience freedom now!
patient safetyThis article focuses on the reconstitution of parenteral medicines and the work that has been carried out at the European level to improve patient safety. Reconstitution may occur in a clinical area, for example, ward, theatre and so on, or within pharmacy. The quality of ...
The purpose of this study was to examine the efficacy and safety of vitamin supplements with resveratrol (Resvega, Thea Laboratories) in patients with diabetic macular edema (DME). Methods Participants in this prospective, pilot study were 23 patients with DME, who were previously treated with ...
The purpose of this study was to examine the efficacy and safety of vitamin supplements with resveratrol (Resvega, Thea Laboratories) in patients with diabetic macular edema (DME). Methods Participants in this prospective, pilot study were 23 patients with DME, who were previously treated with ...
SAFETY DEVICE AGAINST RECURRENCE RISKS FOR RESAIRCH EQUIPMENT.CRISTINI, BRUNO TULLIOCRISTINI BRUNO TULLIO
Real-world safety of treatment with mepolizumab and reslizumab in patients with severe eosinophilic asthmadoi:10.1016/j.jaci.2018.12.301Ordóñez Pinilla, Karen A.Camacho, Beatriz MoyaRodríguez, Consuelo FernandezFernandez Crespo, Jesus F.
Efficacy and safety of reslizumab in severe asthma patients with inadequate response to omalizumab: a multicentre, open-label, pilot studydoi:10.1016/j.jaip.2019.01.017Luis Perez de LlanoBorja CosioChristian DomingoLuis Prieto Andres
Nurse research and the institutional review board: Learn how the IRB process works to ensure participant safety and quality researchMarzinsky, AmySmith-Miller, Cheryl A.American Nurse Today
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary diseaseCOPDLong-acting muscarinic antagonist...
Results There were 1126 patients in the pooled nintedanib group and 565 patients in the pooled placebo group. The mean duration of nintedanib treatment was 28 months. No new safety signals were observed. Incidence rates of bleeding, liver enzyme elevations and cardiovascular events were consistent ...